BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mangia A, Saponaro C, Vagheggini A, Opinto G, Centonze M, Vicenti C, Popescu O, Pastena M, Giotta F, Silvestris N. Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients? Cancers (Basel) 2019;11:E1393. [PMID: 31540486 DOI: 10.3390/cancers11091393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Metovic J, Borella F, D’alonzo M, Biglia N, Mangherini L, Tampieri C, Bertero L, Cassoni P, Castellano I. FOXA1 in Breast Cancer: A Luminal Marker with Promising Prognostic and Predictive Impact. Cancers 2022;14:4699. [DOI: 10.3390/cancers14194699] [Reference Citation Analysis]
2 Fang C, Xu H, Yuan L, Zhu Z, Wang X, Liu Y, Zhang A, Shao A, Lou M, Zhang X. Natural Compounds for SIRT1-Mediated Oxidative Stress and Neuroinflammation in Stroke: A Potential Therapeutic Target in the Future. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/1949718] [Reference Citation Analysis]
3 Rodrigues ED, Gonsalves D, Teixeira L, López E. Frailty-the missing constraint in radiotherapy treatment planning for older adults. Aging Clin Exp Res 2022. [PMID: 36056189 DOI: 10.1007/s40520-022-02200-1] [Reference Citation Analysis]
4 Azim HA, Shohdy KS, Elghazawy H, Salib MM, Almeldin D, Kassem L. Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: A systematic review and meta-analysis. Biomarkers 2022;:1-15. [PMID: 35980714 DOI: 10.1080/1354750X.2022.2112614] [Reference Citation Analysis]
5 Seachrist DD, Anstine LJ, Keri RA. FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer. Cancers (Basel) 2021;13:5205. [PMID: 34680352 DOI: 10.3390/cancers13205205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Almangush A, Bello IO, Heikkinen I, Hagström J, Haglund C, Kowalski LP, Coletta RD, Mäkitie AA, Salo T, Leivo I. Improving Risk Stratification of Early Oral Tongue Cancer with TNM-Immune (TNM-I) Staging System. Cancers (Basel) 2021;13:3235. [PMID: 34209490 DOI: 10.3390/cancers13133235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
7 Brumec M, Sobočan M, Takač I, Arko D. Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:1642. [PMID: 33915941 DOI: 10.3390/cancers13071642] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
8 Miki Y. New Insights into Breast and Endometrial Cancers. Cancers (Basel) 2020;12:E2595. [PMID: 32932889 DOI: 10.3390/cancers12092595] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sonnessa M, Cioffi A, Brunetti O, Silvestris N, Zito FA, Saponaro C, Mangia A. NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. Front Oncol 2020;10:1587. [PMID: 33014808 DOI: 10.3389/fonc.2020.01587] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
10 Al-bedairy I, Shamsa M, Salim SA, Mahdi M, Dawood K, Al Faisal AH. FOXA1 expression in Iraqi women with ER+ breast cancer. Baghdad J Biochem Appl Biol Sci 2021;2:106-19. [DOI: 10.47419/bjbabs.v2i02.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]